Tris Pharma, a pharmaceutical company based in Monmouth Junction, New Jersey, has appointed Sharon Clarke to the position of Chief Commercial Officer to lead the firm’s brand business and launch its first commercial product. The firm has a robust portfolio of approved New Drug Applications and late-stage pipeline of innovative technology based product candidates for the treatment of Attention-Deficit Hyperactivity Disorder.
According to Tris CEO Ketan Mehta, Clarke has been a consultant to Tris over the last several months. Clarke was most recently Vice President of Commercial Operations at Kaléo, a Virginia-based pharmaceutical company building innovative solutions for serious and life-threatening medical conditions. She also held senior positions at The Xtra Mile Group, Meda Pharmaceuticals and MedPointe Pharmaceuticals.
Tris has pioneered the delivery of controlled release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. In December 2015, U.S. Food and Drug Administration (“FDA”) approved Tris’ breakthrough extended-release chewable tablet. Tris’ Nobuse™ technology provides abuse deterrence for opioids and other abuse-prone drugs.